A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

. 2020 May ; 104 (5) : 435-442. [epub] 20200307

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid31883396

Grantová podpora
Pharmacyclics LLC, an AbbVie Company

OBJECTIVE: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. METHODS: This was a phase 2, single-arm, open-label, multicentre study (NCT02902965). The primary endpoint was progression-free survival (PFS). RESULTS: Seventy-six patients were enrolled; 74 received ≥1 dose of study treatment. After median follow-up of 19.6 months, median PFS was 8.5 months (95% CI: 6.2-10.8); median overall survival was not reached. Overall response rate was 57% (95% CI: 45-68), and median duration of response was 9.5 months (95% CI: 6.9-10.6). Grade 3/4 AEs occurred in 73% of patients and fatal AEs occurred in 15% of patients. Incidence of major haemorrhage was 5%; one patient died from cerebral haemorrhage. After an observed increased incidence of serious (42%) and fatal (11%) infections, enrolment was suspended to implement risk-minimisation measures. The safety profile was otherwise consistent with known safety profiles of the individual drugs. CONCLUSION: Ibrutinib combined with bortezomib and dexamethasone elicited clinical responses. However, efficacy assessments conducted at potential restart of enrolment indicated that the targeted PFS could not be reached with additional patient enrolment, and the study was terminated.

Zobrazit více v PubMed

Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7‐30. PubMed

Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19‐37. PubMed PMC

Tai Y‐T, Chang BY, Kong S‐Y, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120(9):1877‐1887. PubMed PMC

Yang Y, Shi J, Gu Z, et al. Bruton tyrosine kinase is a therapeutic target in stem‐like cells from multiple myeloma. Cancer Res. 2015;75(3):594‐604. PubMed PMC

Janssen‐Cilag International NV . IMBRUVICA (ibrutinib) Summary of Product Characteristics 2018. Beerse, Belgium.

Pharmacyclics LLC . IMBRUVICA (ibrutinib) prescribing information 2019. Sunnyvale, CA.

Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF‐kappaB. Cell Signal. 2013;25(1):106‐112. PubMed

Richardson PG, Bensinger WI, Huff CA, et al. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol. 2018;180(6):821‐830. PubMed PMC

Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2018;59(11):2588‐2594. PubMed

European Medicines Agency . Velcade: EPAR ‐ Product Information 2019; Amsterdam, The Netherlands. https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf. Accessed July 28, 2019.

US Food and Drug Administration . VELCADE (bortezomib) for injection, for subcutaneous or intravenous use 2019. Silver Spring, Maryland, USA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf. Accessed July 28, 2019.

Rajkumar SV, Harousseau J‐L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691‐4695. PubMed PMC

Millennium Pharmaceuticals Inc . VELCADE (bortezomib) prescribing information 2019. Cambridge, MA.

Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213‐223. PubMed PMC

Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab‐refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open‐label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241‐250. PubMed

Wang ML, Blum KA, Martin P, et al. Long‐term follow‐up of MCL patients treated with single‐agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739‐745. PubMed PMC

Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open‐label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36(23):2405‐2412. PubMed

Chanan‐Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double‐blind, phase 3 study. Lancet Oncol. 2016;17(2):200‐211. PubMed

Shanafelt TD, Wang V, Kay NE, et al. Randomized phase III study of ibrutinib (PCI‐32765)‐based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG‐ACRIN Cancer Research Group (E1912). Blood. 2018;132:LBA‐4.

San‐Miguel JF, Hungria VTM, Yoon S‐S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double‐blind phase 3 trial. Lancet Oncol. 2014;15(11):1195‐1206. PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...